All In Biotech

NDA 020180 · Organon

Proscar

Finasteride · Oral · 5-alpha Reductase Inhibitor

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jun 19, 1992

Approved uses

4

Original approval plus efficacy supplements

Registered trials

78

20 Phase 3, 6 recruiting

FAERS reports

56,555

36,655 serious, 5,077 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2026.

PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) ( 1.2 ). Limitations of Use : PROSCAR is not approved for the prevention of prostate cancer ( 1.3 ). 1.1 Monotherapy PROSCAR ® is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: - Improve symptoms - Reduce the risk of acute urinary retention - Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use PROSCAR is not approved for the prevention of prostate cancer.

Mechanism: The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these organs. Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable enzyme complex. Turnover from this complex is extremely slow (t ½ ~ 30 days). This has been demonstrated both in vivo and in vitro . Finasteride has no affinity for the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROSCAR · FINASTERIDE 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Finasteride" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue3,717
  • adverse drug reaction2,724
  • erectile dysfunction2,620
  • depression2,600
  • drug ineffective2,431
  • diarrhoea2,356
  • dizziness2,345
  • death2,299
  • anxiety2,145
  • dyspnoea2,104
  • asthenia2,064
  • off label use1,981

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004474
2005527
2006556
2007448
2008520
2009570
2010827
20111,088
20121,319
20131,506
20141,783
20152,803
20163,186
20173,165
20183,770
20193,560
20204,032
20213,416
20223,184
20233,041
20245,048
20257,296
20264,435

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Proscar (Finasteride)

2024 spending

$406K

Beneficiaries

323

1,210 claims

Per beneficiary

$1,256

$5.07 per unit

View as table
YearSpending
2020$0
2021$127,269
2022$470,300
2023$458,548
2024$405,645

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 556 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.